Irisin vs PACAP-27
Head-to-head comparison of Irisin (Irisin (FNDC5 cleavage product)) and PACAP-27 (Pituitary Adenylate Cyclase-Activating Polypeptide-27) — benefits, dosing, side effects, research data, and where to buy.
| Property | Irisin | PACAP-27 |
|---|---|---|
| Category | Diabetes & Metabolic | Diabetes & Metabolic |
| Full Name | Irisin (FNDC5 cleavage product) | Pituitary Adenylate Cyclase-Activating Polypeptide-27 |
| Molecular Weight | ~12.3 kDa | 3158 Da |
| Half-Life | hours | minutes |
| Amino Acids | 112 | 27 |
| Typical Dose | No approved human dose; research use only | Research-only: 0.1-1 nmol/kg |
| Route | IV|SC | Intraperitoneal/Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 79 | 220 |
| Research Status | Pre-clinical | Pre-clinical |
Irisin Benefits
- ✓glucose homeostasis
- ✓energy expenditure
- ✓brown-fat activation
PACAP-27 Benefits
- ✓anti-apoptotic signaling
- ✓insulin secretagogue effect
- ✓reduced ER stress
- ✓islet cytoprotection
Irisin Dosing
not established|not established
PACAP-27 Dosing
0.1-1 nmol/kg in animal studies|10-100 nM in vitro|research-only intermittent dosing
Irisin Side Effects
- ⚠unknown
- ⚠immunogenicity risk
PACAP-27 Side Effects
- ⚠flushing
- ⚠hypotension at high exposure
- ⚠headache
Research Overview
Irisin
Irisin is widely explored in obesity and type 2 diabetes research because it connects exercise biology with metabolic adaptation. Human findings are mixed, so it remains a biomarker and preclinical lead rather than an approved therapy.
PACAP-27
PACAP-27 has been repeatedly shown to support beta-cell survival through cAMP/PKA and related pathways. In experimental models it mitigates cytokine damage, preserves insulin content, and helps maintain islet viability.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.